{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:37:22Z","timestamp":1788219442022,"version":"build-2803163510"},"reference-count":44,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Certain therapies that target CD markers on some blood cells can affect pretransfusion testing. Key examples are anti\u2010CD38, CD47 monoclonal antibody (mAb) therapies such as daratumumab (DARA) and magrolimab, which have presented a challenge for transfusion medicine laboratories around the globe. Scientists have been faced with not only introducing a protocol to provide safe blood to patients but also investigating the most effective method to remove the pretransfusion pan\u2010agglutinating interference caused. A number of papers in the last 5\u2009years have reported on various methods to remove pretransfusion interference; however, most of these studies have been conducted only in a few countries. Most recent reviews on this topic have focused on techniques and reagents to remove pretransfusion interference, and dithiothreitol is currently the gold standard for removing DARA interference. However, it was clear from this review that while many laboratories have developed processes for addressing interference in pretransfusion testing, and DARA interference may not be a major issue, there are still laboratories around the world, that may not have adequately addressed this issue. In addition, the impact of mAb interference on widely used techniques such as flow cytometry is unclear.<\/jats:p>","DOI":"10.1111\/vox.13649","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:23:26Z","timestamp":1714955006000},"page":"785-791","source":"Crossref","is-referenced-by-count":2,"title":["Is drug interference still an issue for pretransfusion testing of patients on anti <scp>CD38<\/scp> and other monoclonal antibody therapies?"],"prefix":"10.1111","volume":"119","author":[{"given":"Nichole","family":"Bevel","sequence":"first","affiliation":[{"name":"School of Dentistry and Medical Sciences Charles Sturt University  Wagga Wagga New South Wales Australia"},{"name":"Transfusion Medicine Laboratory St Vincent's Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan","family":"Thorpe","sequence":"additional","affiliation":[{"name":"Transfusion Medicine Laboratory St Vincent's Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9318-3982","authenticated-orcid":false,"given":"Thiru","family":"Vanniasinkam","sequence":"additional","affiliation":[{"name":"School of Dentistry and Medical Sciences Charles Sturt University  Wagga Wagga New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0141"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.01.016"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13474"},{"key":"e_1_2_9_5_1","first-page":"70","article-title":"Darzalex (daratumumab): first anti\u2010CD38 monoclonal antibody approved for patients with relapsed multiple myeloma","volume":"9","author":"Raedler LA","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2017.05.007"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2017.08.018"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-6247.214358"},{"key":"e_1_2_9_9_1","unstructured":"Australian and New Zealand Society of Blood Transfusion.Guidelines for transfusion and immunohaematology laboratory practice.2021."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102968"},{"key":"e_1_2_9_11_1","volume-title":"EndNote","author":"The EndNote Team","year":"2013"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17006"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13069"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17253"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15033"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16635"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24891"},{"key":"e_1_2_9_19_1","first-page":"25","article-title":"Transfusion management for patients taking an anti\u2010CD38 monoclonal antibody","volume":"40","author":"Bub CB","year":"2018","journal-title":"Rev Bras Hematol Hemoter"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000495773"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15202"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13150"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2017.12.001"},{"key":"e_1_2_9_24_1","first-page":"290","article-title":"New method for overcoming the interference produced by anti\u2010CD38 monoclonal antibodies in compatibility testing","volume":"18","author":"Izaguirre EC","year":"2020","journal-title":"Blood Transfus"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12508"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S213510"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2019-005"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15932"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.1918916"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13789"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14900"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02616"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16687"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16009"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000534273"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.17945\/kjbt.2023.34.1.26"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.47429\/lmo.2020.10.4.330"},{"key":"e_1_2_9_38_1","first-page":"20","article-title":"Pretreatment with Daudi cells eliminates anti\u2010CD47 monoclonal antibody interference in immunohematology testing","volume":"22","author":"Wei H","year":"2024","journal-title":"Blood Transfus"},{"key":"e_1_2_9_39_1","unstructured":"HuntG.PBS listings bring greater hope in fight against multiple myeloma and severe psoriasis; in Department of Health and Aged Care.2020."},{"key":"e_1_2_9_40_1","unstructured":"Services Australia.Systemic light chain amyloidosis. [cited 2024 Feb 28]. Available from:https:\/\/www.servicesaustralia.gov.au\/systemic\u2010light\u2010chain\u2010amyloidosis?context=23021#:~:text=The%20Pharmaceutical%20Benefits%20Scheme%20(PBS diagnosed%20systemic%20light%20chain%20amyloidosis)"},{"key":"e_1_2_9_41_1","unstructured":"National Health Service Blood and Transplant (NHSBT) NBaT.Instructions for Use \u2013 0.2 M DTT. [cited 2024 Feb 28]. Available from:https:\/\/nhsbtdbe.blob.core.windows.net\/umbraco\u2010assets\u2010corp\/30139\/inf844\u2010pdf\u2010243kb.pdf"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2012.01199.x"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12989"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmu.2017.07.006"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106953"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T08:51:06Z","timestamp":1723539066000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,5]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/vox.13649"],"URL":"https:\/\/doi.org\/10.1111\/vox.13649","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,5]]}}}